tbuckley/cabot-search huggingface dataset:
Aprosodia in eight schizophrenic patients
Authors: G Fricchione, M J Sedler, S Shukla
Journal: American Journal of Psychiatry (1986)

Research interest in the "negative" symptoms of schizophrenia has increased in recent years. Given the clinical similarity between affective deficits in schizophrenic patients and aprosodic deficits in stroke victims, the authors conducted a study testing for aprosodia in eight schizophrenic patients. Seven were found to have aprosodia with motor components. Further study of the aprosodias may provide some insight into affective disturbance in schizophrenia.
Elective procedures for normal conditions need high standards
Authors: M. Gilkes
Journal: BMJ (1995)

H pylon is common,6 this is not yet well estab- lished, and the article by Bytzer et al cannot be considered a serious evaluation of the cost effectiveness of such a policy.Studies to address this important question will also have to take into consideration some of the less tangible benefits of a "negative" result on endoscopy.
Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance
Authors: Michaël Cerezo, Abdelali Lehraiki, Antoine Millet, Florian Rouaud, Magali Plaisant, Emilie Jaune, Thomas Botton, Cyril Ronco, Patricia Abbe, Hella Amdouni, Thierry Passeron, Veronique Hofman, Baharia Mograbi, Anne-Sophie Dabert-Gay, Delphine Debayle, Damien Alcor, Nabil Rabhi, Jean-Sébastien Annicotte, Laurent Héliot, Mariano Gonzalez-Pisfil, Caroline Robert, Solange Moréra, Armelle Vigouroux, Philippe Gual, Maruf M.U. Ali, Corine Bertolotto, Paul Hofman, Robert Ballotti, Rachid Benhida, Stéphane Rocchi
Journal: Cancer Cell (2016)
Abstract P2-08-05: Association between the neutrophil-to-lymphocyte ratio (NLR) and the 21-gene recurrence score
Authors: A Srikanthan, PL Bedard, S Goldstein, A Templeton, E Amir
Journal: Cancer Research (2016)

Abstract Introduction: A high neutrophil-to-lymphocyte ratio (NLR) has been reported to be a poor prognostic indicator in several malignancies including breast cancer. It is unknown whether the prognosis associated with high NLR can be explained by other prognostic factors such as proliferation or estrogen receptor signalling. Here we explore the association between NLR and the 21-gene recurrence score (RS). Methods: The associations between RS, NLR, tumor size, histologic grade, and estrogen receptor (ER) and progesterone receptor (PgR) expression (assessed by immunohistochemistry) were explored in sequential women with early-stage, lymph node-negative (or with lymph node micrometastases), ER-positive and HER2-negative breast cancer treated at Princess Margaret Cancer Centre in Toronto, Canada and in whom results of the RS were available. NLR was measured prior to surgery. Patients with a documented history of pre-existing infectious/inflammatory condition were excluded. Associations were explored using simple linear regression and statistical significance was defined as p&amp;lt;0.05. Results: A total of 130 women diagnosed between January 2006 and April 2015 were included in the analysis. Median age was 55 (range 32-79), 87% were lymph node negative and 13% had nodal micrometastases. The median NLR was 2.2 (range 0.9-9.1) and was collected at a median of 12 days prior to surgery (range 0-60). The median RS was 18 (range 0-41). There was no association between RS and NLR (R=-0.10, p=0.31), grade (R=0.13, p=0.15), age (R=-0.05, p=0.58) or tumor size (R=0.06, p=0.48). RS was negatively associated with the magnitude of expression of both ER (R=-0.22, p=0.01) and PgR (R=-0.44, p&amp;lt;0.001). There was no association between NLR and grade (R=0.20, p=0.15), age (R=-0.13, p=0.17), tumor size (R=0.14, p=0.93), ER (R=0.01, p=0.94) or PgR (R=0.13, p=0.23) Conclusion: The poor outcomes associated with high NLR are unlikely explained by proliferation of estrogen receptor signalling. Citation Format: Srikanthan A, Bedard PL, Goldstein S, Templeton A, Amir E. Association between the neutrophil-to-lymphocyte ratio (NLR) and the 21-gene recurrence score. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-08-05.
First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP)
Authors: A. Ravaud, S. Oudard, G. Gravis-Mescam, E. Sevin, S. Zanetta, C. Théodore, M. de Fromont, C. Mahier-Aït Oukhatar, G. Chêne, B. Escudier
Journal: Journal of Clinical Oncology (2009)

5146 Background: Sunitinib (Su) has been approved in metastatic clear cell carcinoma due to high objective response rates (ORR) and a prolonged progression-free survival (PFS). Subgroups analysis of previous studies hypothesized that Su may be active in PRCC. Type I and II papillary RCC pts have a poor prognosis, with limited effective agents. Methods: SUPAP is a single-arm prospective study using a 2-stage design including 21 patients (pts) to achieve a 20% ORR and if ≥ 2 pts have an OR, 20 additional pts will be included. SUPAP is exploring type I and II PRCC separately with an identical design. Main eligibility criteria included type I or II PRCC confirmed by central pathological review, PS 0–1, measurable disease, first line of treatment. Sunitinib was given at 50 mg/d, 4/6 weeks. Primary endpoint was ORR, while safety and time to progression were secondary endpoints. Results: From 10/07 to 11/08, 5 pts with type I and 23 pts with II PRCC were included. The median age was 65 years old. 25 (89%) pts had a nephrectomy. PS was 0 in 14 (56%) pts and 1 in 11 (44%) pts. Using the MSKCC scoring system : 5, 14 and 4 pts were in the favorable, intermediate or poor risk group, 4 undetermined. With a median follow-up of 5 months (0.7–12), 22/28 pts were evaluable for response rate and toxicity. In type II PRCC, 1/23 pts had a partial response (PR), 13/23 pts had a stable disease (SD) with 4 pts with a SD ≥ 12 weeks, 5/23 pts were progressive, 3/23 pts were too early for evaluation and 1/23 was not evaluable. In type I PRCC, none had a partial response (PR), 3/5 pts had stable disease (SD) and 2/5 pts were too early for evaluation. A cardiac infarction occurred during treatment and was considered as related to Su. Toxicity of sunitinib was similar as reported in pivotal phase III with Su in metastatic RCC. 12 pts required a dose reduction at any time mainly for non-hematologic toxicities. Conclusions: Although some activity has been observed, response rate was lower than in clear cell tumors. Updated data will be presented at the meeting. [Table: see text]
HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV-1 replication and cell death
Authors: Scott J. Brodie, Bruce K. Patterson, Deborah A. Lewinsohn, Kurt Diem, David Spach, Phillip D. Greenberg, Stanley R. Riddell, Lawrence Corey
Journal: Journal of Clinical Investigation (2008)

The Trypanosoma species used in this study included a clinically relevant human CSF isolate and bloodstream form (BSF) from a patient with sleeping sickness.A cloned derivative from this parasite termed "IL1852" was originally identified as a T.b. gambiense and was denoted accordingly in the manuscript.However, the authors recently discovered that IL1852 contains the SRA gene, a characteristic only encountered in T.b. rhodesiense (1).Therefore, because ILRI T.b. gambiense IL2343, a clone derivative of STIB386AA that was derived from TH144/78E(020), was later reclassified as a T.b. rhodesiense (2), the authors have reclassified IL1852 as a T.b. rhodesiense to maintain accuracy.While the reclassification affects certain aspects of the conclusions of this work, it does not invalidate the key finding of a difference in the BBB traversal between human and animal trypanosomes that correlates with the greater incidence of CNS infection in human compared with animal parasites.
Aquagenic Keratoderma
Authors: Eduardo David Poletti, Rocío Muñoz-Sandoval
Journal: New England Journal of Medicine (2014)

A 44-year-old otherwise healthy man presented with thickened palms, accompanied by burning pain, pruritus, and edema, after immersing his hands in water. Physical examination after the patient held wet gauze revealed hypopigmented, translucent papules and plaques in both palms.
A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors
Authors: Sheri L. Moores, Mark L. Chiu, Barbara S. Bushey, Kristen Chevalier, Leopoldo Luistro, Keri Dorn, Randall J. Brezski, Peter Haytko, Thomas Kelly, Sheng-Jiun Wu, Pauline L. Martin, Joost Neijssen, Paul W.H.I. Parren, Janine Schuurman, Ricardo M. Attar, Sylvie Laquerre, Matthew V. Lorenzi, G. Mark Anderson
Journal: Cancer Research (2016)

Non-small cell lung cancers (NSCLC) with activating EGFR mutations become resistant to tyrosine kinase inhibitors (TKI), often through second-site mutations in EGFR (T790M) and/or activation of the cMet pathway. We engineered a bispecific EGFR-cMet antibody (JNJ-61186372) with multiple mechanisms of action to inhibit primary/secondary EGFR mutations and the cMet pathway. JNJ-61186372 blocked ligand-induced phosphorylation of EGFR and cMet and inhibited phospho-ERK and phospho-AKT more potently than the combination of single receptor-binding antibodies. In NSCLC tumor models driven by EGFR and/or cMet, JNJ-61186372 treatment resulted in tumor regression through inhibition of signaling/receptor downmodulation and Fc-driven effector interactions. Complete and durable regression of human lung xenograft tumors was observed with the combination of JNJ-61186372 and a third-generation EGFR TKI. Interestingly, treatment of cynomolgus monkeys with JNJ-61186372 resulted in no major toxicities, including absence of skin rash observed with other EGFR-directed agents. These results highlight the differentiated potential of JNJ-61186372 to inhibit the spectrum of mutations driving EGFR TKI resistance in NSCLC. Cancer Res; 76(13); 3942-53. ©2016 AACR.
Abstract B2-32: Networks dynamics and opposite effects of Wnt5a on motility in melanomas
Authors: Mohammed Rasheed, Nidhal Bouaynaya, Lita M. Araysi, Tang Zhuo, Mei Li, Ping Zhou, Kareem El-Kattan, Hassan Fathallah-Shaykh
Journal: Cancer Research (2015)

Abstract Melanoma is an aggressive cancer whose incidence continues to rise worldwide; furthermore, metastatic melanoma is associated with poor prognosis. Wnt signaling may lead to conflicting effects on the biology of melanoma as it may either decrease or increase the incidence of metastasis. Here, we show that Wnt5a enhances motility in 3/5 cell lines and represses motility in the other two. We measured the effects of perturbations of the levels of Wnt5a, HADHB, Pirin, and Mart1 on the levels of the seven molecules, Wnt5a, HADHB, Pirin, Mart1, Ret1, Stc2, and S100B in the five cell lines. The results uncovered unanticipated nonlinear molecular dynamics. Seeking a mechanistic explanation, we built network models consisting of ordinary differential equations representing signed directed graphs of the interactions between the seven molecules in the five cell lines. Simulations validate the results of the perturbation experiments and reveal that the indirect network-mediated effects of a molecule on another may annul or reverse its direct effects. Furthermore, network analysis and biological validation link HADHB and Pirin to motility. In summary, the findings reveal: 1) opposite effects of Wnt5a on motility in melanomas, 2) HADHB and Pirin control motility through their effects on Wnt5a, and 3) molecular targeting yields nontrivial nonlinear molecular dynamics, which are not readily anticipated. Citation Format: Mohammed Rasheed, Nidhal Bouaynaya, Lita M. Araysi, Tang Zhuo, Mei Li, Ping Zhou, Kareem El-Kattan, Hassan Fathallah-Shaykh. Networks dynamics and opposite effects of Wnt5a on motility in melanomas. [abstract]. In: Proceedings of the AACR Special Conference on Computational and Systems Biology of Cancer; Feb 8-11 2015; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(22 Suppl 2):Abstract nr B2-32.
Rogers v Commissioner: denouement of an important right-to-refuse- treatment case
Authors: T G Gutheil
Journal: American Journal of Psychiatry (1985)

After almost 9 years of passage through various courts, the right-to-refuse-treatment case of Rogers v Commissioner of Mental Health has reached its final resolution in Massachusetts. The author outlines the substantive rulings of this decision in contemporary context, its importance for clinicians in general, and its implications for practice. He proposes that the case presents many problematic elements that could possibly impede good clinical care.
Multigene Testing in Localized Prostate Cancer
Authors: Ashley E. Ross
Journal: Journal of the National Comprehensive Cancer Network (2016)

Currently, there are several commercially available multigene tests for risk stratification in prostate cancer. These tests have been validated retrospectively; however, prospective studies are needed to fully establish their clinical roles. In some cases, molecular studies may add value, and updated NCCN Guidelines recommend “consideration” of molecular tests under certain circumstances, such as to help ascertain the likelihood of death from conservative management, of biochemical progression after radical prostatectomy or external-beam therapy, and of developing metastasis after radical prostatectomy or salvage radiotherapy.
Abdominal Surgery
Authors: Claude E. Welch
Journal: New England Journal of Medicine (1975)

LiverBiliary AtresiaKasai et al. initiated a novel approach several years ago when they achieved unusual success in the treatment of biliary atresia by hepatoportoenterostomy.168 Campbell has noted that the Japanese series now totals 215 patients, with a 43 per cent cure rate for infants undergoing the operation before three months of age and 7 per cent after three months.169 Bill has observed that the disease is not congenital but is essentially a hepatitis with a component of sclerosing cholangitis of the extrahepatic ducts.170,171 He believes operation must be carried out before three months of age, that the ducts must . . .
Cryptococcal Meningitis
Authors: J H Jaster, M J Malecha
Journal: New England Journal of Medicine (1996)

Figure 1. A 69-year-old white man had progressively more severe headaches for five weeks, and sudden persistent hearing loss developed four days before admission to the hospital. He had been healthy and had no history suggesting immune compromise or exposure to infectious agents. He was fully alert and oriented and had no neurologic abnormalities on examination, but he had severe bilateral sensorineural hearing loss and papilledema. A test for human immunodeficiency virus antibody was nonreactive. The results of magnetic resonance imaging of the brain and meninges with contrast agent were normal.On lumbar puncture the opening pressure was 52 cm . . .
Investments for Professional People
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Utilization of neuropsychiatric diagnostic tests for general hospital patients with mental disorders
Authors: M Olfson
Journal: American Journal of Psychiatry (1992)

The author's goal was to determine the frequency and distribution of neuropsychiatric diagnostic tests provided to general hospital patients with mental disorders.Data from the 1989 National Hospital Discharge Survey were analyzed to determine the number, proportion, and general characteristics of 11,628 discharged patients with primary diagnoses of mental disorders who underwent computerized tomography (CT) scanning of the head, EEG, and magnetic resonance imaging (MRI) of the brain.Of the discharged patients with mental disorders, 5.1% had received CT scans, 2.8% had received EEGs, and 0.7% had received MRI. These rates were below the rates for patients discharged with primary diagnoses of neurological disorders but above the rates for patients discharged with primary diagnoses of other medical disorders. Among the patients discharged with mental disorder diagnoses, the likelihood of receiving a CT scan or an EEG was greater if the primary diagnosis was an organic disorder or if the secondary diagnosis was a medical disorder. Patients over age 65 were also more likely to have received a CT scan. Hospital size and location had a modest influence on the likelihood of receiving a CT scan or EEG, but the ownership of the hospital and the patient's source of payment were not significant influences.Neuropsychiatric diagnostic testing is selectively utilized in the routine treatment of general hospital psychiatric inpatients. Clinical variables rather than institutional or financial variables appear to be the most powerful predictors of which patients are selected to receive these tests.
HCP-10INTEGRATED DISEASE MANAGEMENT FOR NEURO-ONCOLOGY PATIENTS AND THEIR FAMILIES: PUTTING PATIENT CENTRED CARE INTO PRACTICE
Authors: Emma Daly, Lauren Todorovic, Jo McLeod, Lauren Barker, Victoria Whitman, Brian Anthonisz, Rosemary Higgins, Ron Freilich
Journal: Neuro-Oncology (2015)

BACKGROUND: The Cabrini Neuro-Oncology program was developed to facilitate integration and streamline patient care within a complex heath system. The program encompasses a continuum of care from diagnosis to bereavement. Care is delivered in acute, rehabilitation, outpatient, community and palliative care settings. Within this program the Neuro-Oncology Clinical Nurse Consultant works in collaboration with the neurosurgeon, neuro-Oncologist, allied health, rehabilitation and palliative care services to provide individualised specialist neuro-oncology care to patients and support to carers. In addition to outcomes, it is important to understand the experience of patients and families when evaluating programs. This study assessed the acceptability of the program and aimed to guide further service development. METHODS: Two focus groups were held. Three current patients, eight bereaved carers and one current carer participated in the focus groups. Qualitative focus group data was transcribed in full and analysed thematically using a constant comparison method of thematic analysis. RESULTS: Focus group data indicated that both patients and carers valued the service highly, particularly the patient centred approach that the program offers. Access to information and emotional support throughout the program was seen as invaluable. Other themes that arose included the need for intensive support following diagnosis and after bereavement, as well as support with service navigation and self-management. DISCUSSION: This integrated disease management approach, delivered by a multidisciplinary care team, has been designed to meet the specific needs of patients with primary brain tumours and provide support to them and their carers. The results indicate the benefits of integrated management throughout the continuum of care, highlighting how this approach impacts on the experiences of patients and carers. Further service development will streamline services to improve communication at point of diagnosis and support to carers in bereavement. Opportunities have been identified to provide enhanced and improved access to targeted information.
Comparisons of patients’ satisfaction should take expectations into account
Authors: M. Dizon, E. Linos, S.T. Arron, K. Abuabara, A.M. Ruiz de Luzuriaga, C. Jin, W.J. Boscardin, M.‐M. Chren
Journal: British Journal of Dermatology (2016)

Patients’ experiences have become increasingly important in the assessment of quality of care1,2. For example, the Centers for Medicare & Medicaid Services (CMS) uses Consumer Assessment of Healthcare Providers and Systems (CAHPS) surveys to measure patient experience, and reward providers for providing high quality care through Value-Based Purchasing initiatives3. There is concern, however, that patients’ reports may be related to typically unmeasured characteristics, such as their expectations for care4,5 or frame of mind at the start of a visit6. We report the results of a survey of skin cancer patients’ experiences with care, and how adjustment for expectation fulfillment may affect comparisons of quality between two practice settings.

This article is protected by copyright. All rights reserved.
Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx), and rituximab plus DHAOx (R-DHAOx) for treatment of patients with B-cell non-Hodgkin's lymphoma: Results from two consecutive phase II studies
Authors: D. Machover, B. Delmas-Marsalet, Y. Gumus, S. C. Misra, A. Ulusakarya, N. Brahimi, E. Goldschmidt, N. Frenoy, C. Guettier
Journal: Journal of Clinical Oncology (2004)

6681 Background: To determine, from two consecutive phase II studies, the efficacy of oxaliplatin (L-OHP), cytarabine (ara-C), and dexamethasone (DHAOx), and DHAOx plus rituximab (R-DHAOx), in patients with non-Hodgkin's lymphoma (NHL). Methods: In Study I, treatment consisted of DHAOx (dexamethasone, 40 mg/day, days 1 to 4; L-OHP, 130 mg/m2, day 1; and ara-C, 2,000 mg/m2, every 12 hrs, day 2). In Study II, treatment consisted of R-DHAOx (DHAOx plus rituximab, on day 1, 375 mg/m2). Courses were repeated every 21 days. Patients had failed to achieve a complete response (CR) with initial chemotherapy, were in relapse, or could not receive standard treatment. Results: Response to therapy: Study I: Eight patients (61.5%) achieved a CR, and 1 (8%) had a PR. None of the complete responders has relapsed; they had a median disease-free survival (DFS) of 44.6 months. Study II: Fifteen patients (68%) achieved a CR, and 3 (13.5%) had a PR. None of the complete responders has relapsed; they had a median DFS of 19.8 months. Responses were obtained in lymphomas of follicular, marginal-zone, mantle-cell, and diffuse large B-cell subtypes, and in patients with or without resistance to prior chemotherapy. Disappearance of molecular markers occurred in all of the complete responders whose tumor cells carried markers. Toxicity: Myelosuppression and dose-related peripheral neuropathy were the most prominent toxic effects. Conclusions: DHAOx and R-DHAOx are highly active for salvage treatment of patients with B-cell NHLs, and possess toxicity characteristics which compare favorably to those reported with ara-C plus cisplatin-containing regimens. No significant financial relationships to disclose.